<SUBMISSION>
<ACCESSION-NUMBER>0001144204-06-000182
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20060104
<FILING-DATE>20060104
<DATE-OF-FILING-DATE-CHANGE>20060104
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>06504692
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v032626_6k.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
      AND EXCHANGE COMMISSION</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
      D.C. 20549</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
      6-K</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
      OF
      FOREIGN ISSUER</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to Rule 13a-16 or 15d-16 of</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
      Securities Exchange Act of 1934</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
      the month of January 2006</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
      File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 20pt; FONT-FAMILY: Times New Roman"><strong>pSivida
      Limited</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
      of registrant&#8217;s name into English) </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
      12
      BGC Centre</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
      The
      Esplanade</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
      WA
      6000</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
      of principal executive offices)</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
      by check mark whether the registrant files or will file annual reports under
      cover Form&#160;20-F or Form&#160;40-F). </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
      20-F&#160;<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
      40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(1):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark if the registrant is submitting the Form 6-K in paper as permitted
      by Regulation S-T Rule 101(b)(7):</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
      by check mark whether the registrant by furnishing the information contained
      in
      this Form is also thereby furnishing the information to the Commission pursuant
      to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
      </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">x</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
      "Yes"
      is marked, indicate below the file number assigned to the registrant in
      connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
      </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
      to the requirements of the Securities Exchange Act of 1934, the registrant,
      pSivida Limited, has duly caused this report to be signed on its behalf by
      the
      undersigned, thereunto duly authorized. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
      <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

          <tr valign="top" bgcolor="#ffffff">
            <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">Date:
              January 4,
              2006</font></td>
            <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td colspan="2"><font size="2">pSivida Limited</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;<br>&#160;</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">By:&#160;&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">/s/
              Aaron Finlay</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="FONT-FAMILY: " size="1">&#160;</font></td>
            <td align="left">
              <hr style="COLOR: black" align="left" noshade size="2" width="80%"><font size="2">Aaron
              Finlay</font></td>
          </tr>
          <tr valign="top" bgcolor="#ffffff">
            <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ">&#160;</font></td>
            <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: "><em>Chief
              Financial Officer and Company
              Secretary</em></font></td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div><br><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
      INDEX</u></em></strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
    <div>
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="15%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                99.1:</strong></font></div>
            </td>
            <td align="left" valign="top" width="62%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Several
                new pharma drug delivery evaluation agreements for US
                subsidiary</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: ">-2-</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v032626_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
</title>
</head>
  <body bgcolor="#ffffff"><br>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><img src="logo.jpg"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    <div align="center">
      <table bgcolor="white" cellpadding="0" cellspacing="0" width="100%">

          <tr bgcolor="white">
            <td width="50%"><strong><font size="2">ASX/MEDIA RELEASE</font></strong></td>
            <td width="50%">
              <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><strong><font size="2">5
<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">January</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
                2006</font></font></strong></div>
            </td>
          </tr>

      </table>
    </div>
    <div align="center">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><strong>Several
      new pharma drug delivery </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><strong>evaluation
      agreements for US subsidiary</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">
      <div>
        <hr style="COLOR: black" align="left" noshade size="1" width="100%">
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
      bio-nanotech company pSivida Limited </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(ASX:PSD,
      NASDAQ:PSDV, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      pleased to announce that its wholly owned subsidiary pSivida Inc. (formerly
      Control Delivery Systems, Inc.) has recently entered into a number of new
      evaluation agreements with various companies including large global
      pharmaceutical companies, to evaluate pSivida&#8217;s proprietary platform technology
      for their developmental compounds.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      terms
      of the new evaluation agreements </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">vary,
      but
      are typically 12 months in duration with the costs being borne by the
      counterparty. With these new agreements, pSivida Limited now has evaluation
      agreements with three of the five largest pharmaceutical companies in the
      world.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
      December 2005, pSivida completed the acquisition of </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Control
      Delivery Systems, a private US drug delivery company located in the Boston,
      Massachusetts area. Control Delivery Systems</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">in
      collaboration with Alimera Sciences initiated a Phase III clinical trial in
      October 2005 </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">to
      study
      diabetic macular edema (DME) patients treated using its Medidur&#8482; platform
      technology to deliver fluocinolone acetonide. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">DME
      is
      the leading cause of vision loss for Americans under the age of 65 with
      approximately 500,000 treatable cases in the US alone. </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Medidur&#8482;
      for DME </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">is
      an
      injectable, non-erodible intravitreal device that is administered</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      in an
      office procedure as opposed to a surgical procedure. This implant is designed
      to
      release a constant amount of drug to the back of the eye for a duration of
      between 18 months and 3 years. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Medidur&#8482;
      is the next generation product to Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      which is
      administered in a surgical procedure and licensed to Bausch &amp; Lomb for the
      treatment of chronic, non-infectious uveitis, a sight threatening inflammatory
      eye disease affecting approximately 175,000 people in the US.
      Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">is
      the
      only FDA approved back of the eye treatment for uveitis. Bausch &amp; Lomb told
      investors and analysts in December 2005 that they believe the future for
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Retisert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      is
      bright.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#8220;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">We
      believe these new evaluation agreements come at a time when the ophthalmology
      market is growing strongly and are a reflection of growing interest in pSivida's
      technologies,&#8221; said Mr Gavin Rezos, MD and CEO of pSivida Limited. &#8220;We expect to
      enter into further agreements for pSivida&#8217;s drug delivery products in
      2006.&#8221;</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div align="left">
      <table cellpadding="0" cellspacing="0" width="100%">

          <tr>
            <td align="left" valign="top" width="33%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                Limited</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                Leedman</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                Relations</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                + 61 8 9226 5099</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
            </td>
            <td align="left" valign="top" width="33%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                Public Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                Jedynak</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                E. Janis &amp; Company, Inc</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +1 (312) 943 1100 ext. 12</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
            </td>
            <td align="left" valign="top" width="34%">
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                Swallow / Helena Podd</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                Dewe Rogerson</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                +44 (0)20 7638 9571</font></div>
              <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
            </td>
          </tr>

      </table>
    </div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
      TO EDITORS: </strong></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is a global bio-nanotech company committed to the biomedical sector and the
      development of drug delivery products in particular in oncology and
      ophthalmology.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      owns or has the exclusive rights to use the intellectual property pertaining
      to
      BrachySil&#8482;, Medidur&#8482;, Retisert&#8482; and Vitrasert</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>&#174;</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
      The
      company&#8217;s IP portfolio consists of 70 patent families, 74 granted patents and
      over 290 patent applications.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      owns the rights to develop and commercialise a modified form of silicon
      (porosified or nano-structrured silicon) known as BioSilicon&#8482;, which has
      applications in drug delivery, wound healing, orthopaedics, and tissue
      engineering. pSivida has granted an exclusive licence to its subsidiary, AION
      Diagnostics Limited to develop and commercialise diagnostic products using
      BioSilicon&#8482;, and has also granted an exclusive licence to its subsidriary,
      pSiNutria Limited to develop and commercialise food technology applications
      using BioSilicon&#8482;. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      conducts its operations from offices and facilities near Boston in
      Massachusetts, Malvern in the United Kingdom, Perth in Western Australia and
      Singapore. </font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
      the
      Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
      and in
      Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
      PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
      pSivida is a founding member of the NASDAQ Health Care Index and the Merrill
      Lynch Nanotechnology Index.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
      Company's largest shareholder and a strategic partner is QinetiQ, a leading
      international defence, security and technology company, formed in July 2001
      from
      the UK Government's Defence Evaluation &amp; Research Agency
      (DERA).&#160;QinetiQ was instrumental in discovering BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>(TM)</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      and
      pSivida enjoys a strong relationship with it having access to its cutting edge
      research and development facilities. For more information visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.QinetiQ.com</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
      more
      information, visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
      document contains forward-looking statements that involve risks and
      uncertainties.&#160; The statements are indicated by the use of words such as
      "believes", "expects", "anticipates" and similar words and phrases.&#160;
Although we believe that the expectations reflected in such forward-looking
      statements are reasonable at this time, we can give no assurance that such
      expectations will prove to be correct. Given these uncertainties, readers are
      cautioned not to place undue reliance on such forward-looking statements. Actual
      results could differ materially from those anticipated in these forward-looking
      statements due to many important factors including: our failure to develop
      applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      due to
      regulatory, scientific or other issues, our inability to successfully integrate
      CDS&#8217; operations and employees; the failure of the CDS&#8217; products to achieve
      expected revenues and the combined entity&#8217;s inability to develop existing or
      proposed products. Other reasons are contained in cautionary statements in
      the
      Registration Statement on Form 20-F filed with the U.S. Securities and Exchange
      Commission, including, without limitation, under Item 3.D, "Risk Factors"
      therein. We do not undertake to update any oral or written forward-looking
      statements that may be made by or on behalf of pSivida.</font></div>
    <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
      </div>
      <div id="PN">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````6@``_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0(!`0$"`@(!`0("`@("`@("`@,"
M`P,#`P(#`P0$!`0$`P4%!04%!0<'!P<'"`@("`@("`@("`$!`0$"`@(%`P,%
M!P4$!0<("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(
M"`@("`@("`@(_\``$0@`2@#Z`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0(%`@,$!@8%!0$#!F\!`@,$$04&(1(`!S%!$PA1(F$4<8$RD0FA(_#!
M0K$5T1;A\5(S%R1B&$,T)8(*&7)3)F.21#6B5+(:<S;"TB=%-T;B\H.3H[-D
M52C#TRDXX_-'2%9E*CDZ24I76%E:9G1UA(5G=G=HAH>4E:2EM+7$Q=35Y.7T
M]9:7IJ>VM\;'UM?FY_;W:6IX>7J(B8J8F9JHJ:JXN;K(R<K8V=KHZ>KX^?H1
M``$#`@,$!P8#!`,&!P<!:0$"`Q$`!"$%$C$&0?!180<3(G&!D:&QP0@RT13A
M(_%"%5()%C-BTG(D@L*2DT,7<X.BLF,E-%/BLS4F1%1D154G"H2T&!D:*"DJ
M-C<X.3I&1TA)2E976%E:969G:&EJ='5V=WAY>H6&AXB)BI25EI>8F9JCI*6F
MIZBIJK6VM[BYNL/$Q<;'R,G*T]35UM?8V=KCY.7FY^CIZO+S]/7V]_CY^O_:
M``P#`0`"$0,1`#\`W^.>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO55]U^_
M%8Z$=-,]5'0WH3E[&?63ZE_TJ1=%NGD*XH:&6(A6.+8HFZDH8T8VD)9W3]Y!
MPP9RY:AJ5X4])J+=X.UBPMG_`,M:I5=7/]!O&/\`&5B`!QB2.(H$ZZG_`!V.
MM&'29GP7$^C'HZI61I,&Z;U4>(YSQQKKN2/$*Y8*BC5NP)@73V<>_P`C1ABK
MGTHC6G?R]3K26+41@DRI7DHPI/L]E"O^$AZW^J?K;Z#9\QGK9EF@P7JET9S9
M7Y/S;C6$1O%A.,34-/#/\S!&[R>6_P"E*R*K%;@,M@VT-9G:):6-.PBC7L@W
MYN\\R]:KE(#K2R@D;#`!GSQQX<<)BK5N%U2S7N>KU>YZO5[GJ]7N>KU>YZO5
M[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]
M7N>KU>YZO5[GJ]7N>KU=7%[7U]G*ZA,<:]7?+5ZO<]7J]SU>HM/JB]6/2+TB
M=/WZ@=5ZC%*J&H,D>7\JX%A%?CF-8K4QIO,--34$;VT(O)*R1K<;G%^*+>U6
MZ8308WJWNL\GM^]N"<=@2"5$]``^)('754G]2OQ&?Q28(JGJ?78A^'5Z*,<$
M3KTSPV82=5<YX:]R17U95/Y9#,FACV@V-FCE%FX8ZV+?9XU^X<\Q43?D=Y-Z
MA+Y-C8G^$?W58ZSAI!Z"!UI4,:M;],?I#].GH[R-#T^]/O33#\AX6ZI_.,51
M?/Q?%IE'^6KZ^?=/4.3<C>Q5;V4*-.%EQ>*<5XCC4M;K[G9=DS'=6C80.)VJ
M/F=I^`X0*!3\1SU98MZ7.A!H^F>%2YP]2W7*J_J?Z9^GE(@FK<2S/B4?E)4"
M*X)@H5?SY6/NBRJQ&X'C]C;!Q>/VC;1)VD;V+RNPA@:KEXZ&DC$E1XQT)V]$
MP.-/_P"'3Z1J?T3^D_IUT4JZF/%,\A9\:ZLYBC9G7$<TXNPJ:Z4.Q)94.V&-
MO%(U-K\K?7/>N%7"G^SC=`9)E*+8XK^Y9Z5';[,`.H4>+B2AU7N>KU>YZO5[
MGJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7
MN>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU%#Z]=$<"Q.MQ#J521XU7YGKFIH'I
M*+'Z'!H8!'!Y*3*]>@3W2BW7>"2=.<Z_JT^F#*[VY=WD9%TY?.%""EJ[9MDH
MA&E*PIY.G"$RG6"HG"A;D6=+2`R=(2)VI)],*#_TR]:<Z0YTK.BO4ZN;%,4@
M67^08M+40U4ZRP1^<]/)40NZRJ8[LC!B="+FXM$'T.?4WO,WO,YN7O,X7;A(
M/<N*6EQ04A.HMJ<2I0<!1*DJU*(((D@B%^\N3,]R+AD0.(B/6.%#)UEZ7Y\Q
ME\QYSRMUFQC*"T-"9:;+%.7%#NHZ<NVL<J%3)MU-C8^!YDK]2O89O9F1NLYR
MO/;JQ[MDJ2P@J[J6T$G[5I@KC$P8)F#1/D^9L(TMK:2J3MXX^E5<CKCUB*AO
M\Y^.6(O_`,E"?_FKG!H_51VD_P#.7N_]67^-2?\`R2S_`.-I]@JR?H7TXZAS
M4&1>HV9>MF-8_#B=)'75&496=Z)TJZ8E(W:25BQ3>#?:-1VYVW^E/L8WP=L\
MNWCS+/[NY2\TETVZBHMD.(.E*BI9U:=0,Z1XA@.-1OGF8VX4ME#21!B>.!\J
M2?JEZUYKP?','Z0=-JKY#,V/)$^+8NDL<,T*U+E(8(Y9658F>Q9Y"19;6(N3
MR/OKS^IW>#+<U8W1W;7W=]<A)<<"@A20LPAM*U$);*HU*62-*2F"))I7NQDK
M2T&X>Q2-@\N/7Y5`Z6]+<L97H7ZQYY?'L/QG(KF6:27'J+'EQ"<4X1BD6&)*
M2SO)LCA#EV8@"Y(N:?2?]*]D[>-9_F`NT9A:K@%=XQ<H=5H\2SW04$IE1A!<
M*AQ,8E+O-O)W+*D^'NXX)((Z`)VGR&->Z(^G3,6:^N6+^M+U&8<HZOUU#+@O
M0WILTBU%)TUR?,V]J=2K/&^,8A_E,2J4)`T@B)C0L_49Y\!'=IV<3TG\.BH4
MR'=QUZ^.97@_;$0VC:&D='1K5_&1_BC`23Y<14/Z]SU>KW/5ZO<]7J#OJEU+
MP+I1D^OS=CP:>.`K%AV&QD"6KJI+[(D+:"]B23V4$^'(;[>.VW*>S_=QS-[^
M5)3"4('W..*^U">B8))_A2"8,03#*\M<NG@VGV]`JM#&O6CUHQ:NEDP7^7X!
M2L28,/AHA5.J#_$]27+&W<A0/@.</MYOZS?M+S"[4JR[FV;G!"6@L@=:EZB3
MTD!(ZA4DL[FV:$^*2?./A2YZ:>MW,U-BU-0]3Z"FQ/`ZEPD^.T<)IZJEW&V]
MHU)21!X@`'V7[<E;L._K1\[9S%%OO.TAVU60"ZVG0XW/\12#I6D<0`E48B3X
M2AS+<ILHEDD*Z#L-694E535U+35U'.M31UD:2TM2A#))'(H=64CN"#<<[B9?
M?L7;"'V5!;;B0I*AB"E0D$'B"#(J-EI*3!VBJXNOE1ZEX^J^:EZ?_P!:/ZI`
M47\J_ET=2U'_`+P0^9Y9C!'^4W7MXWYQ;^K>\[;T=H%X,@_F/\N_9=WW(<+?
M]R;U:=(C[]4QQFI$R%.6_E4][HUXS,3M-6+87\Q_+,.^;W?->1#\SOOO\SRQ
MNW7\;]^=F<A+QL6N]GO-"=4[9@3/7.VH\=C48V5/X;52O<]7JB5_G?(UOR]_
M/\J3R-OVM^PVM\;\V*HY.DQ6G5^'5BWXSL_KBZ$P^H\];O\`,4^+8D,^_P!9
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MQBA#7N>KU>YZO5[GJ]7N>KU>YZO4$_6VCAK.G6,K4)2O%`]+(PK,&DQ^$;:E
M!<T4/O2'70C[/?PY`/U-Y<U<[FOAP-E*2@_M+8W:?O2/[@GQ+..!'V_=L!HU
MR99%P(GCL.GATU611M'@OJ*Z85="U/&DV(8."*3`*G+4`$M5\JX%'4C=JIU<
M:-]7.&5@^WE?;/E#K&@)4];?W.T79)A3G=JAE<'$3*Q@J3Q!J2U`KRYP&=AV
MJU<)VBA*ZH_B*9'QKU7X#Z'^AF`R]8LWFDQRI]2&=,.WSX-T_P`(H\%K)%2J
MJ(+H:R2J6&)D)"Q[MK$R$(/HE[2LO_Y=:^6O`?EGHZSW:JQ=;[2&%[Q,Y9:I
M[U>K]HH8I;`Z2.,P#P$P<<*(FO\`DE_XB/X<^.8[:S)J^7HQ_P`ZCZ9_]Z+"
M_P#RCCY]9WTR_P#4.LH_[P[?_E)-05G/_%;G^,?C59W4*1<:]4^=GK7ADBHZ
MJ:,"IP:?,$&VFH$@57H:>[.!;0]E.IYQ#[7W$9GV^7ZGRDI0XH>.V7>(A#(0
M`6$8J&&W8DPH[*DFP&C*TQQ'`Z=IZ:L.Z#8?119!3RJ>B,4E?431_*9?ERY%
MO7:@;Y.H&X.-O^4\=+=N=E/I-L&&-T_V0;"5.K/[.T59I_A&+*H,X?<?N$=%
M1YGQU/XS@!M5J]]#?S)FB>O<]7JUO_Q0?QM.L7H-]45=T"R/T1RUG[!J;+N#
MXS%CV*XABE-5-/B7S&Z,I2>YM7R18]]>'V79.'V]4UC3VJ=NEUN]FOY1#25I
MT@R9G'R-%X]3_P#PHYSUA1CC](W0B@SEEC+L%#%GWK/F*EQNHR__`#F>GC>>
MEHH</>D*Q1R,426>=6D[K':S,HMLA2?O,=5!C>WZE[AL?\+V0M*0-2U`E,D8
M@`$8=!)QZ.D_OX2GXP]/^(+BN;NDG5/)6']->NV4Z'^;X?!A4\[X/C^$)*E/
M/+2QUKR30S4[R)YD1=[JP96T8!%FF5=QB#(J0NQWMJ3O(I3#Z`W<)$X;%#C`
M))!'1)PQZ:.;Z]DK3EOITZ*QPY:^M%4POM$[4R>5?XE0]OKYQR_K;&[HY'EA
M3/<AYW5T:M"=$]<!<>M9<;B%/>KZ8'/PI/\`H:S%D6B@S1@-?/346>L3JHWP
M]I]B2U5$(5410._<JX8L@-S<&Q\`;_55;Y;J6K-Y8/J;;S5YP%&N`IQK2`$-
MD[2E6HJ0#)D&"`84;[V[ZBE0DH`]AZZ%;JUZ1<$ZE9ZBS5AF-QY-HJN`#,%'
M3T:R/452.;2H-\:*64V8D&Y%[7)YD%]0O]79E6^^]2<TMGTV+2T?MDH;"BM8
M)\8$I2DJ3@HXR1,$DFBG*=[5VS&@C41LQV"C-9#RC39"RA@.3Z/$*C%*3+\`
MIZ:MJBAG=%8L`WEJHLH-@`.P',XNRGL\8W3W=MLH9<6\W;(T)4N-1$DB=(`@
M3`$8``8[:#=]=E]XN$`$]%$\ZS>K?-'3+J/F+).'91H,3H\%^5\FNGGJ$D?Y
MBCBJ3<1Z"QDMSF_]2W]8?G>XN^EUDEO9,O-V_=PI2EA1UM(69`,8%4>0H79/
MNFW<VR7"H@F?C%*OUN>H#J3Z;_2%U1]1?2_)F&YZS7TTPJEQNHRCB4M7#2SX
M>E1#\\0]&"X:&!WE7P]W7G5G=JX_/,-.*P+B4G#@2`8J&NT'/+C*<K=NF$A:
MFA,&8@''9T#'TJNC\)#\7K./XB?4?JYTTZC=,,#Z:XWD7!:'',L#!ZZNJOGZ
M5ZYJ&L\P5H!'E-+!;;_B-_#@BS3*A;I!!F:BWL=[97=Y;AUEUM+:D)"A$XB8
M.WHD4^_BZ?BSYH_#GS#T5R;T\Z;8/U*S1U*H\7Q/,%-C%964L=!A]%-3TM,T
M?R5V9II7E'O:`)\>:RO+!<`DF(I1VQ]L#F[+C3;38<4X"3,X`0!L(VX^RCO?
MA_>I;J?ZKO2'D'U(=4\AX;T[Q_J&F*5V#96PV:KGIQA5+6S4E),SUGO[IU@\
MSV;6!'$5[;I;=*09BAYV>[S76;9.B\?0$*7)`$[`2!MZ8GRJD[T-_CZ=;O5;
MZNNCWIRS-T"RKE3`.I6)5]#B&8Z#$L7FK*9*3#*NN5HTJ!L)+4X!OX$\.+S(
MTM-%<[*@K</ZA[O-\Y:LELH2EPD2)D0">GJK8]ZY=9<C^GGI!U%ZW=2<0.&Y
M(Z98558MF"H1=\KQ4R76&)21NEF<K'&M]78#QX0,M%:@D;363.?9TQEUFY<O
M&$-I)/X#K.P==:B]+_PI=]5N9NJ"19']*V5\;R'-/(]'T]A.8J_,\U#&2Y_T
MZAD:(2A!=F6B91["->"D[O-A&*C-8;M_5%FSUY#-LA3?]'Q%4?XTQ_O/I56?
MXLOK$Z=^N;U+9?ZZ=.,&Q/+-#+DK`\(S-E7%X5BK<+QK#ZFN:KI2T;,DJH9E
MVR+;<.ZJ;J#/*[53+12>DU$7;'OI;9]FR;ID%([M((.T*!,CKVX'W#96^MZ"
M?^K'?1W_`.$PR)_[#%%P%7_]W5YGXUT*[._^6!:?[2W_`+X*HS]=G_"B_`>B
M_4O-'2+TI=,<.ZKUV2*NHP[,_53'JNIBP)L1I9#!-#04N'F.6ICC=2IG::-6
M(.P,MF)Q99"5IU+,5`O:#]2S=A=JMK!L.E!(*E3ID=`$$CKD=0(QHEW33_A3
MGZDL+S-1?YY?3SDW-&4C*G\VI,NR8U@>*QP,?>:%\3J\2B9@-0K*H;MN'?BQ
MW=QLCPDS0$RKZJLS0Z/S3#:D<=.I)]I*A[JVZ?3UU[Z;^I_HSD'KMTEQ5\7R
M'U$HA68/-+'Y-3`RR-3STU1'=O+G@EC>*5;FS*;$BQ(5?94VLI5M%9E[N;P6
MV:V2+JW,MK$CIZ"#U@X&AGXU1W7N>KU>YZO4QYFPC^?8!B^#_,5%*V(0/&E1
M254E%4*UKKY<\0+1FX^T`;>S@6WWW>_FV4/VFI:"X@@%MPM+!X:7$@E!G^(`
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M`</::KB7_)J/':-/JY\P!VUD55RN4>LO3?IYT3R#6YAS52+546!8<%P2&>*>
MNEE2B3]&L$;%MQ(MJ`!XD<^ECLY^I7<K<_LORQ[,+QH.-V3/[)*TJ=4H-)\(
M;!*IG"2`!_$0*AV[R>YN+U80DP5''AMZ:(UTYPK,V>,\8]U(>E^8Q#.-56'"
M,-H<X4.6L5\ZJGWD(#YDSIM]P+M%^_8<Y6]C&0YYO1O3<[QZ-;U^X[W;;69-
M63^I:Y(3]SBDQ*0G2`K;)`H;YBZVPP&>"0))05##W5:MD?`Y<N95P;":B6KF
MJH(MU6:ZODQ2I6:9C,Z-52A6EV,Q4-8:`6'._79;NLYDV0,6CA<4XE,J[UXO
MK"E$J4DNJ`*]))2#`$`0`*BV]?#CI4(CJ$#V<*5?!_26O<]7JT%/^%%I(_$=
MQ8C0C(N5;'ZZW@WR#_B?UKGE]3/_`$\O^YH^=;8GIVZ,]-LP?A3]+NE3Y,PV
MDR9G[HQA?]8L#AHX(J>IJL8RC%45-3(D:@-/)-(96D/O%_>O?7@8N'5"Y)G$
M*^=9>;LY):N[H-,:`$+MQ(C:5(!)\R<9VSC6G#^!!C-=@GXH/IW@I9B$QNFS
M;A^(B_\`E(&REB-18_\`0R!&^D<%F=IFV/5'Q%83_3Y<J1O8P!L5K!_TBC7T
M$\_9#R]U)RMB64LS4QJ,-Q``K(A"S03)JDL3$':Z'L?J-P2.8]=K?91D^^N0
MNY3F:-3#HVC!2%#[5H.,*2=G`B0002#TUL+YRV=#B-HJIOJOZ7NHW2Z2?%\/
MA;-N5Z9M\6/4*-\Q3*IN&G@4ET(\76ZCVCGSX?4#]!V^FX:U7ELDWM@@R'6@
M=:`-A<;$J3'%2=2!M*ALJ5LIWGM[KPGPKZ#Q\C2OZ+>KO-F2ZBBP//\`42YN
MRB2J?S!R9,2HDO;<LAUF1?%7][V'PY(WTQ?UBV\&[+S=CO`I5[E\@:SB\T.D
M*.+B1Q2J5?T5"-)1YSNDT\"IKPK]Q_"K6L-Q*@QC#Z'%L+JDKL-Q**.>AK(S
M=)8I5#JRGV$'G?[),ZM,RLV[NU6'&74A:%#$*2H2".H@U%CC:D**58$531ZL
M?^=^Y[^C#?\`RU4W/FB_K"?^HN9C_N'_`$#M5,6ZO_$"/7XFK7<T9&P/J=TC
MS!TVS-`*G+G4#+M5@N/4Y%]]'BF&M13#7_4D//I4W064Y9;D;0VC_?14)9U8
M-W33C*\4K"DGR,@UH/?A'9HQ?TB_BT]/^G&<G?#:BHQW,G3#.,+[H]U75--A
MM.&!\#7TT!%^2OFB0[:R//GTKG3V.7:\FWR2PYA*E-*\S('^]12@_'%Z@XUZ
MC_Q1LU=,\L3-B;Y$3*_3S)U(-1_,:@)53H`/'YW$W0_\1Y7)FPW;2>.-*>WK
M,%YIO:6$8Z-+8\]I_P!Z416]3TGZ7X1T3Z$=/NCV`A?Y/TORMAN`T$B+L$B8
M5AB47F6]KF/<?B>`QUPK65=)K/O)\I189>W;(^UM`2/017SXOP<?^SHGI6_\
M&#&?_8>Q/@\S;_B95<W^Q/\`Z>VV_P`8_P"^*K;2_P"%`N-5^$?AE=5J>BF,
M,>/XYE"AQ$`D;Z=LP4]25-O`M"O`KD8_R@>M9D?44\I&ZSH'\2D#_>@?E56'
M_"7;(&6ZW'O5UU0J\.BJ,UX!!E/`\#Q-T#2TM%B+8E75:1L=5$STL.ZW?8.&
MF\KA\(X8U$7TFY<T5W3Y'C`0D'H!U$^V![*(1_PHBRMEK+'XB.)29<P"CP%L
MRY+R_B>831TT5-\[B,]37PR54PA5=\SK$@9S[QL+GBW(5$V^/2:COZE;1IK>
M;P)"=3:28$223B>O`8UN0^C'!9,R?A\>EW+L6*3X)+CW2')]%'C5*5%31M59
M0I8!/"7!'F1[MRW%KC@3O#%PH_WQ^-9M;C,%W=NV0"1J80)&T2@8CRJJKI7^
M"-Z"_0AU$RMZI.KO7NOQO+?2Z2HK4HNH%3EJERY)7-2R1PSS[Z:#S)86;S8D
MW&\BJ;$@<,G,X?>3H2-O142Y5V$[O9!=)O[AXE+9)API"9@QP$QM`Z0*IX_'
M<]:GHF]7F*=%XO3%7)F_/73JIQ>#.W46GP*HPNDK,*JH(!3TT=3614\M2(YH
MF9?<VJ"2K>\;FV26;S4Z]AJ%/J#WYR'.2T+(ZG&RH*5I@$80),$QC&$=%7?_
M`/"<2KJJG\.DP3SM+%A^?LU0T,;$D11-'0U!5;]AOE9K>TGA+GP_;^E3W],[
MA5NU!X.*^"3\ZOLX2UD'7N>KU>YZO51[^)/ZVNK>-]3<O?AL^A'_`'[>K'J_
M`!U%S_$S_*].<LU$8::LFFBOY-4T+[]Y!,49!4&62(<-["T2$]ZY]H]]07VE
M[\W;ETG)LKQNW?N5P;2=I)X&,9X#9B11Z>C/H;Z;]-?3WTMZ'9PQS%NK.*]-
M\+CH/\Z.,5L\F.5#[C*X6?<66F1F*T\#%ECC`47L2<=.VWZ;-R^T`Z\WM4J>
M`@.H)0Z`-@UI@J`Z%:DXG"IFW"8N,AR]NU;=4L(&)49D^1V#H`V"!2>S=Z(.
MGV'X1C>,85FK%Z?^64M34PTLQHYU+0PM*%W"%#8VMS`/M"_JM]S[++KB\M+R
MZ3W3:UA*N[4/"DJ`D(28P\ZDJTWUN%+"5)3B0.-5DJUT#>T7M]7.%YJ2ZL=Z
M;^B_(N9\H93S7C&:<5\S,-!25M30T_RD*HU3"LQ16>*0V&ZUSKSM7V+?U9NZ
MF?;MV.:WEY<S<L-NE".[2`5H"B`2A1@3%1UF.^3[3RD)2/"2./"C9=.>@W3#
MI=+\[E;+JC&-I4X_5.U56[6T(6231`1W"!;^/.A'8U]*&XVXB^^RNU'YF".]
M<)6Y!VPHX(D8'0$SQF@IF&>W-T(6K#H&`H8>9&T45[GJ]7N>KU:"G_"B[_LX
M[B__`((N5?XUO!OD'_$_J:YY?4Q_T\O^8CYUN%>F;$*3"/PW^@^*U\RT]#AG
M1;+=16SL0%2*')-/([$GL``3P*W`FX/^,?C69^ZC@1NNPH[!;I/_`*#%:1GX
M%]/-6_BB^F5Z=#(L/];)Y2/W8ADS%;L?A[P'!CG)_P`F5SQ%8']@+:CO;;]6
MO_E-5;WW7WU"OT1FP:D&39<P28_#-)0X@:E:>E22%PK1L0DC%@&5K`#0]^<Y
M?JY^L-79<MAH6*KE5RA10O7H0"D@%)\*B2`4F,,",:ZI9#N^+V3JTQU8THN@
M762#K-D^;&:BG@PW,&&U$D&-8-"[.(06+0N/,]XJZ>/M!]G!G](_U*,]I>[B
MKU:4-7;2U)=;22=(F4''&%)X[-04!LI-GV3FS>TC%)&!^-5]>LC*64\J]3Z)
MLL4\6'SX]0"LQ_"X`JQQU+3N@D"+HIE`N1[1?QYQZ_K+.SS=[(-^6SEB4M+N
M60XZVF`D+*U#5`P25@21Q(U?Q5(&YUVZ[;'7B`8!YZ*/1Z2JFNJ>@^336DL(
M&KHJ)F[FGCKYE3ZAV'P'.K']7I?W=QV36!?DZ2ZE,_T`ZL)]!L'4*`^]:$B^
M5'5\!5=GJQ_YW[GOZ,-_\M5-SC)_6$_]1<S'_</^@=JI"W5_X@1Z_$U<?@7_
M`"0\&_[Q*?\`Z0KSZ4=T_P#EE,?[4C_?14/O_>?,UH.?C29%Q3TJ?BNXGU<R
MQ2M2)FZIRIU-RHVJ*V(4T\<=59E_Q5N&2,WC[_)8R=7>VND^5<Z.W.Q7D^]_
MYE`^XI='GQ_WI)-,/X7>7,9];OXP&6^K&8L/,D#9KS+U7SG`UIDIOEJJ;%*2
M-BPL0M=4TT8Y;,E=S::1T12;LEMUY]OH+A8PUJ=5U02H?[T0*^@-BW_)+Q+_
M`+QYO^D9X!AMKHN[]A\J^<G^#C_V=$]*W_@P8S_[#V)\D#-O^)E5S)[$_P#I
M[;;_`!C_`+XJML+_`(4*4\T_X9_41XHRZTN9<GR5##]U/YW%'<_"[`?7P+9%
M_P`4"LQ/J-!_LLX>A2/C5<__``EMQ.B_EGK0P8SJ,1^9R-5"FN-Q@,.-0[@/
M8&%C]7##>48I/G\JC#Z2WDZ+M/']F?\`?ZK_`/\`A1]_V<.IO_">Y:_\K<3X
MNR#_`(G]34=?4Y_T\H_VI'Q56U]T-ZRX!Z>/PJ^BO7/-$1J<"Z4]$,KXY74*
ML$>J^0R=2SI3HQ!`:9PL:DCNPX&;AHKNBD<5'XUE_N]G3>6[HLW2\4MVR%1T
MP@8>NRM/'H=EGU+_`([/KB?!^LW5>?!\N8525N8,P1Q,TF&Y2RS!604_R6!T
M$A\I9G>HBB5W%V-Y)2Y%B*7BW9,X#'YUA=D%OFG:!G^FX=(0`5'H2@$"$C9C
M('O,QB;/\<;T!>E[T*]!?2I@?I_R,<'QO,6/X_#G#/6(5<N(8]C:4N%T\B&J
MGE(4*K/<1Q(D8)T4<39-?.O.$J-##M\[.\IR#++=%HB%%2I43*E0$[3\@`.J
MK>_^$WW_`&;NKO\`PH6:?_*7#>%6?_W?T_&IF^F7_IVS_MJO]]35^G"2LAJ]
MSU>JMO\`%"]=<'H7]/$F8<KT(S+UZZJ57]7/3]DA8C4R5V/52A?F&@4$R14@
M<.R@>^YCC_W0$+\OL^^7!^T;:C3M3W\&0Y=K0-5PX=+:8F5=,<0/>8'&D?\`
MA7>A#$?27TJQGJ5UHJSG+U@>HB;^?^H#J#6-\S7QU%:YK$PI9VN=E.SWF*V5
MYKG55CM;,;SO%0G[1LI%V4[A*RBT+]SXKQ_Q.*.)QQTSU<>D]0%6J<+JEBDS
MG7_F#LV_]ZRO_P#*5^`;M._Z=J]_[QWO^4U4ILO[LGS'QK6WS7U&R_E'$,NY
M6,-9FGJ%G$^5D?I;@E,V)YDQJ0#7Y6BA(;RD[R3R%(8Q=G=0+\^6CL2^G;>W
MM"OS;Y-;E:$?W1Y7@9:&TEQPX##'2)4>"34E;X;_`.69&E(N%$NK^QM`U.+/
M]Z@8QTJ,)'$BKTO3EE_JM/D+)&+]6*JAR^]#A=%!@/33!*Q,0HZ*.&$(LM=B
M40`K:E@`2(0M.G9?-($I^HSL>W?8R?=&PL&GD7"6+=I'>H^QS2@)U(V^%42#
MQ%0VVN]N;A3]R.[*B2&P9TX_Q*_B5TQ"1PG;1G.2)1C7N>KU>YZO5[GJ]6@K
M_P`*+#;\1[%3:]LC95-OKK>#C(/^)_6N>/U,B=Y?]S3\Z&7.7IS_`!J.G7HS
MZ9=/NA_47,/J#](?7G)>!UL&5<O4]#6XY@F'9@P>&NEP6:.KC?$H:91,T0^5
MF:%DT(0'9QA-Q9J>)4(4#SU4>7F[._%MD;35JXIZS>;282`2D*2#I(@K`QCP
MG3'1,4=[\"'\*GKET!ZI8WZLO4SDZ7IIB]%A%7@W2;IW6O"<6#XDRI68A60P
ME_EP(4,,,;$.=[,RJ`NY'G>9H<3H1C0\^GWLBO\`+;I5_>IT*TD(2=N.U1'#
M#``XXG#`3LG=9>DV#=8<G5&6L1D^1KX&\_`,9";VI*I5*AK7%T8$JZWU'Q`/
M,6/J5^GS+>T?=I>6W)[MU)ULN1);<`@&,)21X5"<09&(!&9>3YJNS>UC$<1T
MBJOZGH/ZC.F..22Y=P7$Q4@%(L>P"HD=)H[^)IV60`]]KJ.<);WZ2^VC<7-%
M*RYBX"]@=M%J(4GS00L`]"TI\JDU.>Y==(\9'DK]:>LG^ECK3U&QT8AG.GJ,
MMT57*&QC,.+3>;72+^\4B9WD=[=M]A\>"?LX^@?M-WSS;\QG25VK2U`N/7"M
M3I'&$$E:E1LU:4_WU,WF]%G;MPW"CP`V?A5K^5<LX3DW+F"Y6P.$T^$X%3QT
M]%&3=BJ#5F/BS&Y8^)//H'W!W(R_=O)6,KLDZ;>W0$)&TP.)/$DR2>))-17=
M7*WG"M6TFJV/45T'ZM9SZPYNS)EG)DV*X)B/R/R5>D]&BR>5A\$+V$LRL+,I
M&HYQ&^L_Z3.T/>;M(OLRRRP6]:N]UI6%M@'2RVDX*6#@I)&(X5(^[V>VC-FE
M"U0H3T])ZJLVPB&6GPG#*>9/+F@IX$E33W66-5(T]A'.Y^[MLMG+V6UB%)0D
M$=!"0#4:/$%9(Z:UY_Q]_P`/WK3ZO<#]/6?_`$Y=-9.HO4?(-9B^#YJPVFJL
M/I*@X%B<$=9#(7Q&>G1D@J*8@`,2#*=._!MD=\AHD*,`UC-]1/9S?9TTP[9M
MEQU!((!`\)@@XD;"#[:2_P"`3^'7UT])>,^H7JMZD^FL_3;/&:*?"<O9$PJI
MJ\-K)'PF-WQ*NF#8=/4!1),(%`+`_HSIVY?/+]#L!!D4D^G;LTO\F4^_>MEM
MQ0"4@P<-IV$\=/LK9%Q&-YL/KH8EWR2PRK&OM9D(`UX'Q63K@E)K2,_#)_"W
M]>_0WU^^GOJ[U6].N(9/Z<Y/QG%*G,F9YL4R_/%2P3X-7TT;M'25\LIW22JO
MNH>_!EF.9L+84E*I)K`[LK[)=X;#>-BYN&"AI"B293AX2."B=IK;<]:OIJPS
MU?\`I;ZR^G7$\07!WZCX48<#QQTWI0XM1SQXCA]0R@$E(ZF",N!J5N!P*VEP
M6G`KHK,G?C=A&<Y4[9J,=X,#T$&4GV@3U5I+]`?11^-5Z+.O.*P>G7HWFG)>
M?<6C?`\3SGAT&"8IE/$J&299%:6LQ7SL/:$,HD1Y0KH?!6N.#!^]M'D>,@CG
MUK!3=S<+?G(LP(LFUH6?#(`*2/,RCKQV=1H5_6I^#C^)YFW.>2NH68(,4]6W
M5[J'@0Q'K+G.'%<(2AP7%?G)H*?!Z5L3J*-GCIZ9$-XXEB!8A%`%RS9YM;A)
M'V@;*-]_.Q/>E^X0\O5=/+3*U2F$F3X1)&P1L$8P,!6UC@/I=Q?J=^&+D_TB
M=1Z=LFYIS!T>P7)V9(9&29L(QJ'*]/0W<TS.K_+548+;&(;;H;'@:7<@7)6,
M1JGWUES:;J.7.ZJ,O>\"RPE!_O5!`'#H-:;'3+T+?C'>ASKW/CO0?HEF[!.H
MF$K487#G_+5'A^.Y?Q3#ZAT+!IJD34DE-*8TDVU**5(!959=!:[?6CR(41%8
M2Y3V>[ZY!F)7:-+2X)&I(U)(/7!20<#CZ@$8&9]6/X4/XOO7W*62NO77?$ZK
MU`=<<P5\^'U'2>GQ;!2<IX$M,:E)2XJ*/#XC+/=6@HU8#1F=B2%36F:6K:BE
M.">FA5OGV0;Y9DPB[NR7[@F-`*?`G;TA(D\$X<>-;`OX'/IUZV^E[T78ETMZ
M_=/:KIKGI,[8_B,6!U510532T%;24'DSJ^'3U";6:-UL6!NIT[<(LX?0X]*3
M(BLC.P;=J^RK(RQ=MEMSO%&#!P(3C@3T&KC.%5357"21(HWEE<1Q1`M)(QL%
M51<DD^`YZM$Q5%>/=%,S>HW\<>BS=U9PB9^D'I#Z:8/F#H+0SP/_`"[%<9QV
MJ>)J^,O[CO35+2[B-5>&&_87-TO!NT@;5''GG;4#W.1.9EOT'+@?L;9H*;'`
MD_Q>A)]4IZ*O7X45/-`WUP]0O1+TV9*K.H?7;J;A'3#*-&&/\SQ2J2%ZAU`/
ME4T"[IJB4WTCA1G/@..LL+<,)$FB7/=X['+&"]=.);1UG;U`;2>H`FJ@<9]?
MGJ1]=6%8WA?H:R"_0STTEI:+-WKJZ@X5,Z5%.Z&*6/*N7!^FKZAKD1R2DH#H
MZH;'@8[2<[R#(LD>N,Z6$VNDI6/$2H*$%("942H$@!(GHJ,,MWTSO>5X-Y(V
M6F9_N[@Z/Z"3M/6<.!"30=Y"Z39*Z#X/C>`]&,MX_B.8<VQB+JCU^S*)\0SS
MG`BUTJ:LI_HE#<72AI]L8'V@3?G!#ZF/JSSK/LO_`+.[K6+F69$W*=#;90IT
M?WP2/"D\4R5*VK49TC)'L_[+[#)UFY=67[Q?W.K.I9/F=@Z`(`\\:MD]/_7O
M+V)X1T]Z7S97QK#,PTE!!0&KEH0*`O14ANWG;P0K+'I=>^G,]/I"^K3*+[+<
MKW87:7;5XAE#.I38[J6F\3KU2`0G"4C$QUT]G^1.)6MX*24DSMQQ-'"YT=H(
MU[GJ]7N>KU>YZO5H@?\`"A;(.?<Q?B(8MB67<BXUF##CD?*Z#$*#"<0K("ZF
MMW+YE-"ZW%]1?3@TR)U(8Q/&L`?J/RJY>WCU(05#0G8/.MQ[T0TM50^C+TF4
M5=2R45;1]-LD15='-&\4T4L>6J-61TD`964BQ!%P>!2\,O*\S\:S2W";4C([
M5)P(9;_WT4:'B:A97N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N
M>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]01>H'+&;L[=!NM>3,@50
MHL]YMREF/#,EUA=8A%BM?@]12TC%VT6TKJ=Q[=^.L*"5@G9-$V\=J\_E[S3)
MAQ2%!/F4D#WUK;=+/Q\^N'2'`Z#HYZJ/0/G*MZ[Y&A@P?$Y\$CJ:1L2J*6):
M?S):/$*1GB>4IN)ADE1B=R66PX?.Y*E7B0K`UC1E'U`WUFC\M?6:^_1X<)&J
M,)((,3U$@[10XT_K`_&P]9JR81Z;/1QA?HRR-BUPG5[J'+/)B5-3N=HE@I\3
MIX"S6-QMPZ8?$=^-?E;1K[U:CU<_.CM.^6_&=C396HM$'^-R9'EJ`]R%4,70
MO\$3(,^?*'KOZ^NL>-^NCK@@23R,Q2S#*5!*IWB.&@EDD>>)#]E)&6&W^X#C
M+V;JC2V-(]]'F0]AEN;C\UFKJKM_^^G0.J-I`Z#"?[VKQ\/P[#\)H*+"\*H8
M<,PS#8HX,.PZGB2&"GAB4(D<<<8"HJJ``H``'"<XF34[--I0D)2(`V`;*F<]
M5Z]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]S
MU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW/5ZO<]7J]SU>KW
M/5ZO<]7JX_O#M^WGJ]7+GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO
M5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ
@]7N>KU>YZO5[GJ]7N>KU>YZO5[GJ]7N>KU>YZO5__]D_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
